Forecast: Antihypertensive Medicine Sales in Germany

In 2023, antihypertensive medicine sales in Germany were stable, leading into the forecast for 2024 and beyond. From 2024 to 2028, the sales are projected to begin at $4.8 and slightly decline to $4.7 US Dollars PPP per capita. The year-on-year change from 2023 to 2024 showed no significant growth, implying market saturation or stabilization, with subsequent years following this flat trend.

Future trends to watch include:

• Innovation in drug development could influence the market.
• Healthcare policy adjustments may impact affordability and access.
• Demographic changes, such as an aging population, may drive demand.
• Increased awareness and diagnosis of hypertension can expand market size.